The mediating role of cPLA2 in IL-1 beta and IL-6 release in LPS-induced HeLa cells

Cell Biochem Funct. 2004 Jan-Feb;22(1):41-4. doi: 10.1002/cbf.1052.

Abstract

Studies were conducted to characterize a HeLa cell model by which the roles of the 85-kDa phospholipase A2 (cPLA2) in interleukin-1 beta (IL-1 beta) and interleukin-6 (IL-6) release could be evaluated. At first, untreated HeLa cells were compared with lipopolysaccharide (LPS)-treated HeLa cells. The latter resulted in cPLA2 overexpression and an increased trend of IL-1 beta and IL-6 release. The indicated doses of 85-kDa cPLA2 antisense oligonucleotide directed against the initiation site were then used to block cPLA2 in LPS-induced HeLa cells. The process led to a dose-dependent decrease in cPLA2 protein with no noticeable change of cPLA2 mRNA. Compared with that of LPS added only, a reduction of IL-1 beta and IL-6 levels in the supernatants of transfected cells following the repression of cPLA2 was observed. These results suggested that 85-kDa cPLA2 may mediate the signalling cascades by which IL-1 beta and IL-6 were released in LPS-induced HeLa cells.

MeSH terms

  • HeLa Cells
  • Humans
  • Interleukin-1 / biosynthesis*
  • Interleukin-6 / biosynthesis*
  • Lipopolysaccharides / pharmacology*
  • Oligodeoxyribonucleotides, Antisense / pharmacology
  • Phospholipases A / antagonists & inhibitors
  • Phospholipases A / metabolism*
  • Phospholipases A2
  • Polymerase Chain Reaction
  • RNA, Messenger / biosynthesis
  • Radioimmunoassay

Substances

  • Interleukin-1
  • Interleukin-6
  • Lipopolysaccharides
  • Oligodeoxyribonucleotides, Antisense
  • RNA, Messenger
  • Phospholipases A
  • Phospholipases A2